Own Pain Relief Solution Store In Your City | Franchise Sales & Distribution Call us on 8691006638
Therapeutic anticoagulation plays a vital role in managing moderate to high-risk thrombotic conditions where effective clot control is essential. LMWH therapies are widely utilized due to their clinical efficiency and predictable response.
NADROBARA® 5700 IU is developed by RIHCA and marketed through RAWIACARE, supporting advanced therapeutic anticoagulation across global healthcare environments.
Used for treatment of thromboembolic disorders such as DVT and pulmonary embolism.
| Specifications |
| 5700 IU / 0.6 ml |
| Prefilled Syringe |
| DVT treatment |
| Pulmonary embolism |
| High-risk patients |
| Hospitals & ICU |
